All
Tecentriq Granted Priority Review to Treat Lung Cancer
May 7th 2018The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) to be used in combination with Avastin (bevacizumab), carboplatin and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).
High Percentage of Caregivers Report Feeling Depressed, Study Finds
May 5th 2018Eighty-nine percent of caregivers of young adult colorectal cancer survivors are depressed because they can’t take the pain away, according to findings from the Raymond Foundation, an advocacy organization that aims to eradicate colon cancer.
FDA Approves Combination for Rare Thyroid Cancer Type
May 4th 2018The Food and Drug Administration (FDA) approved the two-drug combination Tafinlar (dabrafenib) and Mekinist (trametinib) to treat patients with metastatic or unresectable anaplastic thyroid cancer (ATC), whose tumors harbor the BRAF V600E mutation.
Immunotherapy in GU Cancers: Combinations Are the Next Step
May 4th 2018Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.
NCI-Designated Cancer Centers Yield Improved Mortality Rates in Acute Myeloid Leukemia
May 3rd 2018As suspected, the average early mortality rate improved overall during the study period. But while evaluating the data, researchers noticed something interesting about the difference in early mortality at the NCI-designated cancer centers compared to non-NCI-designated cancer centers.
FDA Approves CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma
May 2nd 2018The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) – a CAR-T cell therapy – for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).